Jeremy Cook, MD
Dermatology · Woodbury, MNNPI 1982865317
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 81 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 11.7% — the pattern of someone who eats at a lot of different presentations.
Across 81 payments — averaging $16.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$155
- Regeneron Healthcare Solutions, Inc.$127
- Incyte Corporation$105
- Johnson & Johnson$76
- Sun Pharmaceutical Industries Inc.$70
- Lilly USA, LLC$67
- plus $731 from 24 others
What the payments were for
- Food & beverage$1,332100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 9 | $155 |
| Regeneron Healthcare Solutions, Inc. | 8 | $127 |
| Incyte Corporation | 6 | $105 |
| Johnson & Johnson | 4 | $76 |
| Sun Pharmaceutical Industries Inc. | 5 | $70 |
| Lilly USA, LLC | 5 | $67 |
| Boehringer Ingelheim | 4 | $66 |
| Pfizer | 4 | $65 |
| E.r. Squibb & Sons, L.L.C. | 4 | $58 |
| LEO Pharma Inc. | 3 | $57 |
| Amgen | 3 | $54 |
| Revance Therapeutics, Inc. | 1 | $52 |
| Dermira, Inc. | 3 | $40 |
| Kyowa Kirin, Inc. | 2 | $31 |
| Sanofi | 2 | $31 |
| Kerecis Limited | 1 | $31 |
| Bristol Myers Squibb | 2 | $29 |
| Galderma Laboratories, L.p. | 2 | $26 |
| Mimedx Group, Inc. | 1 | $21 |
| Verrica Pharmaceuticals Inc. | 1 | $19 |
| Novartis | 1 | $18 |
| Arcutis Biotherapeutics, Inc. | 1 | $17 |
| Dermavant Sciences, Inc. | 1 | $17 |
| AbbVie | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
| Prugen, Inc. Pharmaceuticals | 2 | $15 |
| Sandoz | 1 | $15 |
| Smith+Nephew | 1 | $14 |
| Promius Pharma LLC | 1 | $13 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $11 |
How this compares
$1,332 in reported general payments places this provider in the 80th percentile of 273 dermatology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cosentyx Unoready PenSecukinumab | 12 | $86,968 |
| Dupixent SyringeDupilumab | 12 | $46,413 |
| Dupixent PenDupilumab | 12 | $45,166 |
| EucrisaCrisaborole | 14 | $10,180 |
| Ketoconazole | 233 | $5,984 |
| Betamethasone Dipropionate | 124 | $4,661 |
| Ivermectin | 13 | $4,061 |
| Fluticasone Propionate | 134 | $2,397 |
| Metronidazole | 57 | $2,328 |
| Triamcinolone Acetonide | 219 | $2,323 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 99 | $2,311 |
| Clobetasol Propionate | 77 | $2,101 |
| Azelaic Acid | 14 | $2,077 |
| Calcipotriene | 17 | $1,942 |
| Tacrolimus | 14 | $1,866 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEucrisa | $65 | $10,18014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 273 dermatology providers in Minnesota.
Other dermatology in Woodbury
- Kristina ShafferEagan$538K
- Margareth Pierre-LouisMinneapolis$439K
- Maria HordinskyMinneapolis$85K
- Afsaneh AlaviRochester$71K
- Todd SeelhammerSaint Paul$63K
- Brittney SchultzMinneapolis$52K
- David PearsonMinneapolis$46K
- Phillip EckerWayzata$31K
- Noah GoldfarbMinneapolis$30K
- Saranya WylesRochester$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.